Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 2/2018

01-02-2018 | Original Contributions

Glucose Metabolism Parameters and Post-Prandial GLP-1 and GLP-2 Release Largely Vary in Several Distinct Situations: a Controlled Comparison Among Individuals with Crohn’s Disease and Individuals with Obesity Before and After Bariatric Surgery

Authors: Daniéla Oliveira Magro, Everton Cazzo, Paulo Gustavo Kotze, Ana Carolina Junqueira Vasques, Carlos Augusto Real Martinez, Elinton Adami Chaim, Bruno Geloneze, José Carlos Pareja, Cláudio Saddy Rodrigues Coy

Published in: Obesity Surgery | Issue 2/2018

Login to get access

Abstract

Background

This study aims to compare the post-prandial curves of glucose, insulin, GLP-1, and GLP-2 among individuals with Crohn’s disease (CD), obese individuals before and after bariatric surgery, and healthy controls.

Methods

This an exploratory cross-sectional study that involved five groups of patients (two groups of individuals with CD—active and inactive), bariatric patients (pre- and post-surgery, who were their own controls), and a distinct separated control group of healthy volunteers. C-reactive protein (CRP) levels and the post-prandial curves of glucose, insulin, GLP-1, and GLP-2 curves were assessed and compared.

Results

The pre-RYGB group presented significantly higher levels of CRP than the post-RYGB (p = 0.001) and the control group (p = 0.001). The inactive CD group presented a higher post-prandial GLP-1 area under the curve (AUC) than the pre-RYGB group (p = 0.009). The post-RYGB group presented significantly higher AUCs of GLP-2 than the pre-RYGB group (p < 0.0001), both inactive and active CD groups (p < 0.0001 in both situations), and the control group (p = 0.002). The pre-RYGB group presented a significantly higher AUC of glucose than the post-RYGB (p = 0.02) and both active and inactive CD groups (p = 0.019 and p = 0.046, respectively). The pre-RYGB group presented a significantly higher AUC of insulin than the control (p = 0.005) and both CD groups (p < 0.0001).

Conclusions

Obesity is associated with an inflammatory state comparable to the one observed in CD; inflammation may also be enrolled in the blockade of GLP-2. CD individuals present a more incretin-driven pattern of glucose metabolism, as a way to prevent hypoglycemia and compensate the carbohydrate malabsorption and GLP-2 blockade.
Literature
1.
World Health Organization. Global status report on noncommunicable diseases 2014. WHO: Geneva; 2014. p. 1–298.
2.
Singh S, Dulai PS, Zarrinpar A, et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):110–21.CrossRefPubMed
3.
Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.e42. quiz e30CrossRefPubMed
4.
Nic Suibhne T, Raftery TC, McMahon O, et al. High prevalence of overweight and obesity in adults with Crohn’s disease: associations with disease and lifestyle factors. J Crohns Colitis. 2013;7(7):e241–8.CrossRefPubMed
5.
6.
7.
Ahn LB, Huang CS, Forse RA, et al. Crohn’s disease after gastric bypass surgery for morbid obesity: is there an association? Inflamm Bowel Dis. 2005;11(6):622–4.CrossRefPubMed
8.
Kotze PG, Bremer-Nones R, Kotze LM. Is there any relation between gastric bypass for morbid obesity and the development of Crohn’s disease? J Crohns Colitis. 2014;8(7):712–3.CrossRefPubMed
9.
Shoar S, Shahabuddin Hoseini S, Naderan M, et al. Bariatric surgery in morbidly obese patients with inflammatory bowel disease: a systematic review. Surg Obes Relat Dis. 2017;13(4):652–9.CrossRefPubMed
10.
11.
Bregenzer N, Hartmann A, Strauch U, et al. Increased insulin resistance and beta cell activity in patients with Crohn’s disease. Inflamm Bowel Dis. 2006;12(1):53–6.CrossRefPubMed
12.
Nagahori M, Hyun SB, Totsuka T, et al. Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol. 2010;45(10):1008–13.CrossRefPubMed
13.
Karrasch T, Obermeier F, Straub RH. Systemic metabolic signaling in acute and chronic gastrointestinal inflammation of inflammatory bowel diseases. Horm Metab Res. 2014;46(6):445–51.CrossRefPubMed
14.
Meek CL, Lewis HB, Reimann F, et al. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides. 2016;77:28–37.CrossRefPubMed
15.
16.
Cazzo E, Pareja JC, Chaim EA. Weight loss surgery and the surrogate insulin resistance markers HOMA, TyG, and TG/HDL-c in relation to metabolic syndrome. In: Preedy VR, Rajendram R, Martin CR. Metabolism and pathophysiology of bariatric surgery: nutrition, procedures, outcomes and adverse effects. London: Academic Press; 2017. p. 325–31. https://​doi.​org/​10.​1016/​B978-0-12-804011-9.​00055-8.
17.
Jacobsen SH, Olesen SC, Dirksen C, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012;22(7):1084–96.CrossRefPubMed
18.
Cazzo E, Gestic MA, Utrini MP, et al. GLP-2: a poorly understood mediator enrolled in various bariatric/metabolic surgery-related pathophysiologic mechanisms. Arq Bras Cir Dig. 2016;29(4):272–5.CrossRefPubMedPubMedCentral
19.
LeRoux CW, Borg C, Wallis K, et al. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg. 2010;252(1):50–6.CrossRef
20.
Taqi E, Wallace LE, de Heuvel E, et al. The influence of nutrients, biliary-pancreatic secretions, and systemic trophic hormones on intestinal adaptation in a Roux-en-Y bypass model. J Pediatr Surg. 2010;45(5):987–95.CrossRefPubMed
21.
22.
Suzuki S, Ramos EJ, Gonçalves CG, et al. Changes in GI hormones and their effect on gastric emptying and transit times after Roux-en-Y gastric bypass in rat model. Surgery. 2005;138(2):283–90.CrossRefPubMed
23.
Huda MS, Wilding JP, Pinkney JH. Gut peptides and the regulation of appetite. Obes Rev. 2006;7(2):163–82.CrossRefPubMed
24.
Vahl T, D'Alessio D. Enteroinsular signaling: perspectives on the role of the gastrointestinal hormones glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide in normal and abnormal glucose metabolism. Curr Opin Clin Nutr Metab Care. 2003;6(4):461–8.PubMed
25.
Bendet N, Scapa E, Cohen O, et al. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection. Scand J Gastroenterol. 2004;39(7):650–6.CrossRefPubMed
26.
Tsukahara T, Watanabe K, Watanabe T, et al. Tumor necrosis factor α decreases glucagon-like peptide-2 expression by up-regulating G-protein-coupled receptor 120 in Crohn disease. Am J Pathol. 2015;185:185–96.CrossRefPubMed
27.
Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439–44.PubMed
28.
Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–53.CrossRefPubMedPubMedCentral
29.
National Institutes of Health. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992;55(2 Suppl):615S–619S.
30.
Lee WJ, Huang MT, Wang W, et al. Effects of obesity surgery on the metabolic syndrome. Arch Surg. 2004;139(10):1088–92.CrossRefPubMed
31.
Dorman RB, Serrot FJ, Miller CJ, et al. Case-matched outcomes in bariatric surgery for treatment of type 2 diabetes in the morbidly obese patient. Ann Surg. 2012;255(2):287–93.CrossRefPubMed
32.
Mumme DE, Mathiason MA, Kallies KJ, et al. Effect of laparoscopic Roux-en-Y gastric bypass surgery on hemoglobin A1c levels in diabetic patients: a matched-cohort analysis. Surg Obes Relat Dis. 2009;5(1):4–10.CrossRefPubMed
33.
Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–76.CrossRefPubMedPubMedCentral
34.
Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–61.CrossRefPubMed
35.
Batsis JA, Romero-Corral A, Collazo-Clavell ML, et al. Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin Proc. 2008;83(8):897–907.CrossRefPubMedPubMedCentral
36.
Inabnet 3rd WB, Winegar DA, Sherif B, et al. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg. 2012;214(4):550–6.CrossRefPubMed
37.
Cazzo E, Gestic MA, Utrini MP, et al. Influence of insulin resistance status on the development of gallstones following Roux-en-Y gastric bypass: a prospective cohort study. Obes Surg. 2016;26(4):769–75.CrossRefPubMed
38.
39.
de Hollanda A, Jiménez A, Corcelles R, et al. Gastrointestinal hormones and weight loss response after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2014;10(5):814–9.CrossRefPubMed
40.
le Roux CW, Borg C, Wallis K, et al. Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. Ann Surg. 2010;252(1):50–6.CrossRefPubMed
41.
Romero F, Nicolau J, Flores L, et al. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-en-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc. 2012;26(8):2231–9.CrossRefPubMed
42.
43.
Tigas S, Tsatsoulis A. Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol. 2012;25(1):37–44.PubMedPubMedCentral
44.
Gonçalves P, Magro F, Martel F. Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel. Inflamm Bowel Dis. 2015;21(2):453–67.CrossRefPubMed
45.
Sellin JH, Hart R. Glucose malabsorption associated with rapid intestinal transit. Am J Gastroenterol. 1992;87(5):584–9.PubMed
46.
Bjørneklett A, Fausa O, Midtvedt T. Bacterial overgrowth in jejunal and ileal disease. Scand J Gastroenterol. 1983;18(2):289–98.CrossRefPubMed
47.
Raithel M, Weidenhiller M, Hagel AF, et al. The malabsorption of commonly occurring mono and disaccharides: levels of investigation and differential diagnoses. Dtsch Arztebl Int. 2013;110(46):775–82.PubMedPubMedCentral
48.
Hering NA, Fromm M, Schulzke JD. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol. 2012;590(5):1035–44.CrossRefPubMedPubMedCentral
49.
Tamura A, Hayashi H, Imasato M, et al. Loss of claudin-15, but not claudin-2, causes Na+ deficiency and glucose malabsorption in mouse small intestine. Gastroenterology. 2011;140(3):913–23.CrossRefPubMed
50.
Caradonna L, Amati L, Magrone T, et al. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res. 2000;6(3):205–14.PubMed
51.
Herlitz-Cifuentes HS, Garces PC, Fernandez LI, et al. Effect of systemic inflammation on the function of insulin and glucose metabolism in rheumatoid arthritis. Curr Diabetes Rev. 2015;12(2):156–62.CrossRefPubMed
52.
Guerrero-Romero F, Simental-Mendía LE, Rodríguez-Morán M. Association of C-reactive protein levels with fasting and postload glucose levels according to glucose tolerance status. Arch Med Res. 2014;45(1):70–5.CrossRefPubMed
53.
Schmidt PT, Ljung T, Hartmann B, et al. Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. Eur J Gastroenterol Hepatol. 2005;17:207–12.CrossRefPubMed
54.
Sigalet DL, Kravarusic D, Butzner D, et al. A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients. Can J Gastroenterol. 2013;27:587–92.CrossRefPubMedPubMedCentral
55.
Coy CSR, Calixto A, Vasques AC, et al. Evaluation of GLP-2 levels in Crohn’s disease. Inflamm Bowel Dis. 2016;22(Suppl 1):S58.CrossRef
56.
Divella R, De Luca R, Abbate I, et al. Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J Cancer. 2016;7(15):2346–59.CrossRefPubMedPubMedCentral
57.
Cooke AA, Connaughton RM, Lyons CL, et al. Fatty acids and chronic low grade inflammation associated with obesity and the metabolic syndrome. Eur J Pharmacol. 2016;785:207–14.CrossRefPubMed
58.
Tarantino G. Gut microbiome, obesity-related comorbidities, and low-grade chronic inflammation. J Clin Endocrinol Metab. 2014;99(7):2343–6.CrossRefPubMed
59.
van Avesaat M, Troost FJ, Ripken D, et al. Ileal brake activation: macronutrient-specific effects on eating behavior? Int J Obes. 2015;39(2):235–43.CrossRef
60.
Meloni AR, DeYoung MB, Lowe C, et al. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15(1):15–27.CrossRefPubMed
61.
Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov. 2009;8(5):369–85.CrossRefPubMed
62.
Eriksson LS. Splanchnic exchange of glucose, amino acids and free fatty acids in patients with chronic inflammatory bowel disease. Gut. 1983;24(12):1161–8.CrossRefPubMedPubMedCentral
63.
Lee YS, Shin S, Shigihara T, et al. Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes. 2007;56(6):1671–9.CrossRefPubMed
64.
Zietek T, Daniel H. Intestinal nutrient sensing and blood glucose control. Curr Opin Clin Nutr Metab Care. 2015;18(4):381–8.CrossRefPubMed
65.
Magro D, Kotze P, Camargo M, et al. Serum levels of lipopolysaccharides and CD26 in patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23(Suppl 1):S90.
66.
Olszanecka-Glinianowicz M, Zahorska-Markiewicz B, Janowska J, et al. Serum concentrations of nitric oxide, tumor necrosis factor (TNF)-alpha and TNF soluble receptors in women with overweight and obesity. Metabolism. 2004;53(10):1268–73.CrossRefPubMed
67.
Cartier A, Lemieux I, Alméras N, et al. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men. J Clin Endocrinol Metab. 2008;93(5):1931–8.CrossRefPubMed
68.
Gentile S, Guarino G, Bizzarro A, et al. Infliximab does not interfere with insulin secretion, insulin resistance and production of GAD and islet cell antibodies in patients with Crohn’s disease. Diabetes Obes Metab. 2002;4(4):276–7.CrossRefPubMed
69.
Rosenvinge A, Krogh-Madsen R, Baslund B, et al. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol. 2007;36(2):91–6.CrossRefPubMed
70.
Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013;9(1):25–53.CrossRefPubMedPubMedCentral
71.
Pina T, Armesto S, Lopez-Mejias R, et al. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol. 2015;29(7):1325–30.CrossRefPubMed
Metadata
Title
Glucose Metabolism Parameters and Post-Prandial GLP-1 and GLP-2 Release Largely Vary in Several Distinct Situations: a Controlled Comparison Among Individuals with Crohn’s Disease and Individuals with Obesity Before and After Bariatric Surgery
Authors
Daniéla Oliveira Magro
Everton Cazzo
Paulo Gustavo Kotze
Ana Carolina Junqueira Vasques
Carlos Augusto Real Martinez
Elinton Adami Chaim
Bruno Geloneze
José Carlos Pareja
Cláudio Saddy Rodrigues Coy
Publication date
01-02-2018
Publisher
Springer US
Published in
Obesity Surgery / Issue 2/2018
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-017-2851-y

Other articles of this Issue 2/2018

Obesity Surgery 2/2018 Go to the issue

Original Contributions

Is Concomitant Cholecystectomy Necessary for Asymptomatic Cholelithiasis During Laparoscopic Sleeve Gastrectomy?

Original Contributions

Mandatory Risk Assessment Reduces Venous Thromboembolism in Bariatric Surgery Patients

How I Do It

Evolution and Standardisation of Techniques in Single-Incision Laparoscopic Bariatric Surgery

Letter to the Editor

Liver Dysfunction with Both Roux-en-Y and One-Anastomosis Gastric Bypass Is Almost Exclusively Seen with Longer Than Standard Limb Lengths

Original Contributions

Laparoscopic Nissen Fundoplication Plus Mid-gastric Plication for Treatment of Obese Patients with Gastroesophageal Reflux Disease

Original Contributions

Converting a Sleeve Gastrectomy to a Gastric Bypass for Weight Loss Failure—Is It Worth It?